Introduction {#s1}
============

Parkinson\'s disease (PD) is the second most prevalent neurodegenerative disorder, the etiology of which remains unknown. Mitochondrial dysfunction, including complex I (CI) deficiency, are frequently observed in pathologic specimens. To elucidate the underlying molecular events, intensive research has focused on identifying the causative gene mutations for inherited forms of PD. An impressive array of disease-causing mutations have been found including autosomal recessive mutations in *PARK6* which encodes PTEN-Induced Kinase 1 (PINK1), a mitochondrially targeted serine/threonine kinase, and *PARK2*, encoding the cytoplasmic E3 ubiquitin ligase Parkin [@pgen.1004815-Kitada1], [@pgen.1004815-Valente1]. Previous work has shown that PINK1 and Parkin regulate several cellular processes that impinge on mitochondrial homeostasis [@pgen.1004815-Clark1]--[@pgen.1004815-WoodKaczmar1], including the fission-fusion dynamics and trafficking of mitochondria [@pgen.1004815-Poole1]--[@pgen.1004815-Ziviani1], the degradation of damaged mitochondria [@pgen.1004815-Matsuda1]--[@pgen.1004815-Vincow1], inter-organelle communication [@pgen.1004815-Cali1], and activity of CI of the electron transport chain [@pgen.1004815-Flinn1], [@pgen.1004815-Mortiboys1], [@pgen.1004815-Muftuoglu1], [@pgen.1004815-Morais1], [@pgen.1004815-Morais2]. However, the mechanisms by which PINK1 and Parkin affect these processes is incompletely understood.

In order to identify functional partners of PINK1 we performed a cell based RNAi screen to identify genes that either phenocopy or suppress *PINK1* phenotypes. In *Drosophila* cells lacking *pink1* or *parkin* steady state levels of Marf are increased causing excess fusion of the mitochondrial network [@pgen.1004815-Poole1], [@pgen.1004815-Ziviani1], [@pgen.1004815-Poole2]. This imbalance in mitochondrial fission-fusion at least partially contributes to the observed organismal phenotypes -- enlarged and disrupted mitochondria, muscle degeneration, male sterility, and associated behavioral deficits and neurodegeneration -- since they can be partially rescued by genetic interaction with fission (*Drp1*) or fusion (*OPA1* and *Marf*) genes to restore the balance of normal mitochondrial morphology [@pgen.1004815-Poole1], [@pgen.1004815-Yang1]. We used this phenotype to screen for factors that impact on mitochondrial morphology and which may play a role in PINK1/Parkin function. Our RNAi screen identified multiple hits including a subunit of CI, ND42/NDUFA10. Given the link between CI deficiency and PD, we selected ND42/NDUFA10 for further characterization.

Knockdown of *Drosophila ND42* phenocopied *pink1* RNAi, causing excessive mitochondrial fusion. Genetic studies in *Drosophila* reveal that overexpression of *ND42* or its co-chaperone *sicily* is sufficient to rescue behavioral deficits in *pink1* mutants through restoration of CI activity. In contrast, overexpression of neither *ND42* nor *sicily* rescued *parkin* mutant flies, and attenuation of the mammalian homolog, *NDUFA10*, in HeLa cells only modestly reduced mitophagy. Furthermore, *NDUFA10* overexpression cannot restore Parkin translocation to mitochondria in the absence of PINK1, suggesting that ND42 selectively rescues *pink1* mutants through a mechanism independent of mitophagy. Our study provides additional evidence in support of a role for PINK1 in CI activity, and further highlights separable functions of PINK1 and Parkin. Future characterization of the other factors from our screen promises to shed additional light on the functional roles of PINK1 and Parkin.

Results {#s2}
=======

An RNAi screen for suppressors or phenocopiers of *pink1* RNAi-induced mitochondrial fusion {#s2a}
-------------------------------------------------------------------------------------------

To identify new components in PINK1-Parkin pathway we performed an RNAi screen in *Drosophila* cells, using a subset library enriched for kinases and phosphatases, for genes that alter mitochondrial morphology ([Figure 1A](#pgen-1004815-g001){ref-type="fig"}). In particular, we sought to identify genes whose knockdown could either phenocopy or suppress the *pink1* RNAi-induced excess fusion. dsRNA treated cells were imaged live using MitoTracker Red to fluorescently label the mitochondrial network. The mitochondrial morphology in each image was scored as primarily falling into one of four categories based on control knockdown phenotypes ([Figure 1B](#pgen-1004815-g001){ref-type="fig"}). Control (*DsRed*) dsRNA treated cells showed a typical mix of short-round and long-tubular mitochondria. This category was scored 2. Cells treated with dsRNA against the fly mitofusin homologue, *Marf*, caused a complete fragmentation of the mitochondrial network as expected and were scored 1. *pink1* RNAi resulted in a tubular, highly interconnected network, as previously reported [@pgen.1004815-Poole1], [@pgen.1004815-Ziviani1], scoring 3. RNAi against the pro-fission factor *Drp1* caused mitochondrial hyperfusion and peri-nuclear clumping. Being qualitatively different from the *pink1* RNAi phenotype and an extreme result of hyperfusion this category scored 4.

![A cell based RNAi screen to identify phenocopiers and suppressors of *pink1* RNAi-induced mitochondrial hyperfusion.\
(A) Schematic of the RNAi screen protocol (see [Methods](#s4){ref-type="sec"} for details). (B) Representative images of *Drosophila* S2R+ cells for mitochondrial morphology following dsRNA treatment of the indicated genes, stained with MitoTracker Red and imaged live (top row). Fluorescence images are converted to binary (B&W) and inverted to clarify the mitochondrial morphology (bottom row). Numbers represent the designated 'morphology score': 1, fragmented; 2, wild type; 3, fused/tubular; 4, hyperfused/clumped. (C) Comparison of morphology score of screen library amplicons in WT and *pink1* RNAi backgrounds. Solid-line box depicts those amplicons that phenocopy *pink1* RNAi (box limits: mean ± s.d. *pink1* control). Dashed-line box depicts amplicons which suppress *pink1* RNAi-induced fusion back to WT morphology (box limits: mean ± s.d. *DsRed* control). Controls for fragmentation (*Marf)* and fusion (*Drp1*) are shown. Scale bar  = 10 µm.](pgen.1004815.g001){#pgen-1004815-g001}

The screen was performed on a library of selected genes mostly comprising kinases and phosphatases but with additional genes of interest. The effect on mitochondrial morphology was assessed in two backgrounds; one in a wild type background to identify manipulations that phenocopy *pink1* RNAi tubulation, and another in a *pink1* RNAi background to identify manipulations capable of suppressing the *pink1* phenotype. The results from the two screens were cross-referenced to further refine the selection of possible hits ([Figure 1C](#pgen-1004815-g001){ref-type="fig"}). The limits of the regions considered to phenocopy or suppress were defined by the mean ± standard deviation for *pink1* or *DsRed* dsRNAs respectively. The gene targets whose dsRNAs either phenocopy or suppress *pink1* RNAi are summarized in [Table 1](#pgen-1004815-t001){ref-type="table"} and [Table 2](#pgen-1004815-t002){ref-type="table"}.

10.1371/journal.pgen.1004815.t001

###### List of genes that phenocopy *pink1* dsRNA induced mitochondrial fusion.

![](pgen.1004815.t001){#pgen-1004815-t001-1}

  Phenocopiers                                                                                                                           
  -------------- --------------------- -------------------------------- ---------------------------------------------------------------- --------------
  CG4523                 pink1             Serine/Threonine Kinase                           PTEN--induced kinase 1                        NP_115785
  CG2277                CG2277                     Unknown                       5\'--nucleotidase domain--containing protein 1            NP_689942
  CG32505              Pp4--19C          Serine/Threonine Phosphatase      serine/threonine--protein phosphatase 4 catalytic subunit       NP_002711
  CG42341               Pka--R1             cAMP Dependent Kinase        cAMP--dependent protein kinase type I--beta regulatory subunit    NP_002726
  CG10564                Ac78c            Adenylate Cyclase Activity                        Adenylate cyclase type 8                       NP_001106
  CG10261                aPkc              Serine/Threonine Kinase                         protein kinase C iota type                      NP_002731
  CG7004           Four wheel drive     Phosphatidylinositol 4--Kinase           phosphatidylinositol 4--kinase beta isoform 2            NP_001185703
  CG11870               CG11870                 Protein Kinase                           NUAK Family SNF1--like kinase                     NP_055655
  CG1747                  Sk1                 Sphingosine Kinase                              Sphingosine Kinase 1                         NP_068807
  CG6343                 ND42                 NADH Dehydrogenase                                    NDUFA10                                NP_004535
  CG34412         Tousled like kinase           Protein Kinase                  serine/threonine--protein kinase tousled--like 2           NP_036033
  CG42317                 Csk                  Tyrosine Kinase                   tyrosine--protein kinase C-terminal Src Kinase            NP_004374

10.1371/journal.pgen.1004815.t002

###### List of genes that suppress *pink1* dsRNA induced mitochondrial fusion.

![](pgen.1004815.t002){#pgen-1004815-t002-2}

  Suppressors                                                                                                                                 
  ------------- ----------------- ---------------------------------- ------------------------------------------------------------------------ -------------------------
  CG5656             CG5656              Alkaline phosphatase                                  Alkaline Phosphatase                                NP_001170991.1
  CG8128             CG8128            Nudix hydrolase activity                    uridine diphosphate glucose pyrophosphatase                        NP_803877
  CG33991        nuclear fallout     Rab and microtubule binding                              Rab11 FIP3/Rab11 FIP4                            NP_055515.1/NP_116321.2
  CG4266             CG4266                  mRNA binding                                             RBM16                                          NP_055707.3
  CG7899             Acph--1               Acid Phosphatase                    prostatic acid phosphatase isoform TM--PAP precursor                NP_001127666.1
  CG7431             CG7431               Tyramine Receptor                               Alpha--1b adrenergic receptor                               NP_000670
  CG31759            CG31759                   unknown                                      2′5′--phophodiesterase 12                                 NP_808881
  CG17559         doughnut on 2                Receptor                          tyrosine--protein kinase RYK isoform 2 precursor                     NP_002949
  CG10975            Ptp69D              Tyrosine Phosphatase         receptor--type tyrosine--protein phosphatase alpha isoform 2 precursor          NP_543030
  CG5361             CG5361              Alkaline Phosphatase         alkaline phosphatase, tissue--nonspecific isozyme isoform 1 precursor           NP_000469
  CG3980              Cep97              Protein Phosphatase                                          Cep97                                           NP_078824
  CG3525         easily shocked          Ethanolamine Kinase                                  Ethanolamine kinase 1                                  NP_061108.2
  CG3494             CG3494                    unknown                              Leucine rich repeat containing protein 40                         NP_060238
  CG11660            CG11660                Protein Kinase                                 Serine/threonine kinase RIO1                              NP_113668.2
  CG1637             CG1637                Acid Phosphatase                             Iron/Zinc purple acid phosphatase                          NP_001004318.2
  CG40448            Pp1--Y2         Serine/Threonine Phosphatase                     Serine/threonine phosphatase PP1 gamma                          NP_002701
  CG17746            CG17746         Serine/Threonine Phosphatase                             Protein phosphatase 1A                                  NP_808820
  CG7180             CG7180              Tyrosine Phosphatase         receptor--type tyrosine--protein phosphatase kappa isoform b precursor          NP_002835
  CG31299            curled                    Unknown                                              nocturnin                                         NP_036250
  CG6860              Lrch                     Unknown                              Leucine rich repeat and calponin homology                         NP_116162
  CG3051              SNF1A         AMP--activated protein kinase         5\'--AMP--activated protein kinase catalytic subunit alpha--2               NP_006243
  CG34356            CG34356                Protein Kinase                                     SCY1--like protein 2                                   NP_060458
  CG42366            CG42366                Protein Kinase                                 Serine/Threonine Kinase ICK                                NP_057597
  CG3530             CG3530        Tyrosine/Serine/Threonine kinase                                Myotubularin                                       NP_000243

While there are several interesting candidates for further investigation in both suppressors and phenocopiers (see [Discussion](#s3){ref-type="sec"}), a specific motivation for this work was to identify additional components of the PINK1-Parkin pathway that regulate mitochondrial dynamics and mitophagy. An attractive candidate that could fulfill this role would be a mitochondrially localized protein. Notably, we identified *ND42*, which encodes a subunit of CI of the electron transport chain, as a phenocopier; knockdown of *ND42* caused excess tubulation similar to *pink1* knockdown. Importantly, CI activity has been shown to be specifically affected in various models of *pink1* deficiency, supporting ND42 as an attractive target for analysis in pink1 function.

*ND42* knockdown specifically phenocopies *pink1* RNAi induced mitochondrial hyperfusion {#s2b}
----------------------------------------------------------------------------------------

CI is a very large, multi-subunit complex comprising of around 44 subunits, consisting of a hydrophobic portion embedded in the inner membrane and a hydrophilic portion extending into the matrix [@pgen.1004815-Janssen1], [@pgen.1004815-Vinothkumar1]. In order to assess the specific versus general effect of attenuating CI subunits on mitochondrial morphology, several additional subunits were analyzed. dsRNAs targeting 6 other subunits from different subdomains (α, β or λ) were generated and the effect of knockdown on mitochondrial morphology was assessed.

We confirmed that *ND42* knockdown caused excess mitochondrial fusion in a WT background, indistinguishable from *pink1* knockdown, but did not further enhance the *pink1* phenotype ([Figures 2A, 2B](#pgen-1004815-g002){ref-type="fig"}, and [S1](#pgen.1004815.s001){ref-type="supplementary-material"}). In contrast none of the other selected subunits induced fusion; 4 subunits had no effect on morphology while 2 subunits caused fragmentation ([Figures 2C and 2D](#pgen-1004815-g002){ref-type="fig"}). Further analysis of one of these subunits, CG7712, which did not perturb mitochondrial morphology, also did not modify the *pink1* phenotype. These results support the specificity of the effect observed with *ND42* knockdown.

![*ND42* RNAi but not other complex I subunits phenocopies *pink1* RNAi.\
(A) *ND42* RNAi in *Drosophila* S2R+ cells stained with MitoTracker Red causes tubulation of the mitochondrial network, similar to *pink1* RNAi. *ND42* RNAi does not further perturb morphology in conjunction with *pink1* RNAi. (B) Quantification of mitochondrial morphology as in A, scored in triplicate experiments. (C) RNAi of selected subunits of complex I or rotenone treatment do not phenocopy *pink1* RNAi. (D) Quantification of morphology scored in triplicate experiments as in C. Histograms indicate mean ± s.d. of triplicate experiments. Inverted, binary images are shown below each fluorescence image to aid clarity of mitochondrial morphology. n\>30 cells per experiment. Scale bar  = 10 µm.](pgen.1004815.g002){#pgen-1004815-g002}

*ND42* overexpression can rescue *pink1* but not *parkin* mutants {#s2c}
-----------------------------------------------------------------

Since *ND42* RNAi phenocopies loss of *pink1* in cells we assessed whether loss of *ND42* may phenocopy *pink1* mutants *in vivo*. *Drosophila* mutant for *pink1* exhibit characteristic locomotor deficits in climbing and flight, associated with degeneration of the musculature and profound disruption of mitochondria [@pgen.1004815-Clark1], [@pgen.1004815-Park1]. In agreement with previous observations [@pgen.1004815-Zhang1], we found that knockdown of *ND42* in all tissues is lethal, consistent with the subunit playing a critical role in this essential metabolic enzyme.

Due to the essential nature of this gene, and lack of *pink1* phenocopy, we did not further characterize *ND42* loss-of-function. We hypothesized that, since *pink1* mutants show CI deficiency, overexpressing *ND42* may suppress *pink1* phenotypes. While *ND42* overexpression of two independent transgenes driven by the strong ubiquitous driver *daughterless* (*da*)-*GAL4* had no effect on motor performance in a wild type background ([Figures 3A and 3B](#pgen-1004815-g003){ref-type="fig"}), we found that expression of either transgene was able to significantly restore climbing and flight ability in *pink1* mutants ([Figures 3C and 3D](#pgen-1004815-g003){ref-type="fig"}). However, *ND42* overexpression only partially restored flight muscle and mitochondrial integrity ([Figure 3E](#pgen-1004815-g003){ref-type="fig"}), but was not able to improve the male sterility ([Figure S2A](#pgen.1004815.s002){ref-type="supplementary-material"}).

![*ND42* or *sicily* overexpression can rescue *pink1* mutant phenotypes in flies.\
Overexpression of two *ND42* transgenes, *ND42* and *ND42-HA*, in a wild type background has no effect on climbing (A) or flight behavior (B). In *pink1^B9^* mutants, climbing (C) and flight ability (D), normalized to control, is significantly rescued by overexpression *ND42* or *sicily*. Histograms indicate mean ± s.e.m. (E) Transmission electron microscopy of flight muscle shows partial rescue of mitochondrial disruption. Scale bar  = 1 µm. Overexpression was driven by the ubiquitous driver *da-GAL4*. Control genotype is *da-GAL4*/+. Number of animals tested, n\>50. \* *P*\<0.05, \*\*\* *P*\<0.001, \*\*\*\* *P*\<0.0001, One-way ANOVA with Bonferroni correction. Comparisons are with control (A, B) or *pink1^B9^* mutants (C, D).](pgen.1004815.g003){#pgen-1004815-g003}

Genetic interaction studies in *Drosophila* have linked *pink1* and *parkin* in a common pathway with *pink1* acting upstream of *parkin* [@pgen.1004815-Clark1], [@pgen.1004815-Greene1], [@pgen.1004815-Park1]. To further characterize the putative action of ND42/NDUFA10 in the PINK1-Parkin pathway, we tested whether *ND42* overexpression could also rescue *parkin* mutants. Surprisingly, we found that overexpression of *ND42* was not able to rescue any *parkin* phenotypes tested, including locomotor behaviors, muscle and mitochondrial integrity, and male sterility ([Figures 4A--4C](#pgen-1004815-g004){ref-type="fig"}, and [S2B](#pgen.1004815.s002){ref-type="supplementary-material"}).

![*ND42* or *sicily* overexpression does not rescue *parkin* mutant phenotypes in flies.\
In *park^25^* mutants, climbing (A) and flight ability (B), normalized to control, is not rescued by *ND42* or *sicily* overexpression. Histograms indicate mean ± s.e.m. (C) Transmission electron microscopy of flight muscle shows widespread disruption of mitochondrial integrity. Scale bar  = 1 µm. Overexpression was driven by the ubiquitous driver *da-GAL4*. Control genotype is *da-GAL4*/+. Number of animals tested, n\>50. \* *P*\<0.05, \*\*\* *P*\<0.001, \*\*\*\* *P*\<0.0001, One-way ANOVA with Bonferroni correction. Comparisons are with *pink1^B9^* mutants.](pgen.1004815.g004){#pgen-1004815-g004}

Recently it was reported that *Drosophila* sicily acts as a co-chaperone to bind and stabilize ND42 in the cytoplasm, promoting its mitochondrial import and the formation of CI [@pgen.1004815-Zhang1]. Supporting a potential role for *sicily* in pink1 function, we found that knockdown of *sicily* in *Drosophila* cells phenocopied *pink1* mitochondrial hyperfusion ([Figure S3](#pgen.1004815.s003){ref-type="supplementary-material"}). Since sicily promotes ND42 stability, and overexpression of *ND42* can rescue *pink1* mutant phenotypes, we hypothesized that *sicily* overexpression may also rescue *pink1* mutants. Indeed, we found that *sicily* overexpression rescued *pink1* mutant locomotor and mitochondrial phenotypes comparable to *ND42* overexpression ([Figures 3A--3E](#pgen-1004815-g003){ref-type="fig"}). Also, overexpression of sicily failed to rescue similar *parkin* mutant phenotypes ([Figures 4A--4C](#pgen-1004815-g004){ref-type="fig"}), mirroring the effects of ND42. Together these results demonstrate a genetic interaction of *ND42* and *sicily* with *pink1* but not *parkin*.

NDUFA10 minimally affects Parkin translocation and mitophagy {#s2d}
------------------------------------------------------------

The fact that *ND42* overexpression can rescue *pink1* but not *parkin* mutants would be consistent with it acting in a common pathway between PINK1 and Parkin. An intensively studied field of PINK1-Parkin function is the autophagic turnover of mitochondria, termed mitophagy [@pgen.1004815-Youle1]. In HeLa cells overexpressing YFP-Parkin, depolarization of the mitochondrial membrane with the protonophore carbonyl cyanide 3-chlorophenylhydrazone (CCCP) causes a rapid stabilization of PINK1 on the outer mitochondrial membrane, which stimulates the re-distribution of cytoplasmic Parkin to co-localize with mitochondria ([Figures 5A and 5B](#pgen-1004815-g005){ref-type="fig"}). Prolonged exposure to CCCP induces substantial degradation of the mitochondria ([Figures 5C, 5D](#pgen-1004815-g005){ref-type="fig"}, and [S4](#pgen.1004815.s004){ref-type="supplementary-material"}). These phenomena are almost completely abolished by *PINK1* knockdown ([Figures 5A--5D](#pgen-1004815-g005){ref-type="fig"}) [@pgen.1004815-Matsuda1]--[@pgen.1004815-Geisler1], [@pgen.1004815-Vincow1].

![*NDUFA10* knockdown slightly reduces CCCP-induced Parkin translocation and mitophagy.\
(A) In HeLa cells stably transfected to express YFP-Parkin, before CCCP toxification (0 h) YFP-Parkin (green) has a diffuse cytoplasmic distribution in control (ctrl) siRNA treated cells. Following 4 h CCCP, YFP-Parkin co-localizes with mitochondria labeled with ATP5A immunostaining (red). *PINK1* siRNA treatment almost completely abolishes YFP-Parkin translocation. (B) Quantification of YFP-Parkin translocation as in A. (C) Stably transfected HeLa cells expressing YFP-Parkin, before CCCP treatment (0 h, ctrl) have a normal ("High") mitochondrial content. Following 24 h treatment with CCCP, a high proportion of control cells (ctrl) show complete degradation ("none") or perinuclear aggregated ("low") mitochondria, visualized by ATP5A immunostaining (red). *PINK1* siRNA treatment almost completely abolishes mitophagy. (D) Quantification of mitochondrial content as in C. Histograms indicate mean ± s.d. of triplicate experiments. n\>30 cells per experiment. Scale bar  = 20 µm. \* *P\<*0.05, \*\* *P\<*0.01, \*\*\* *P\<*0.001, Student\'s *t*-test compared with respective conditions in control siRNA.](pgen.1004815.g005){#pgen-1004815-g005}

We next analyzed the effect of the human homolog of *ND42*, *NDUFA10*, on Parkin translocation and mitophagy. We found that *NDUFA10* knockdown had a modest but significant effect on Parkin translocation, though clearly not as much as loss of *PINK1* ([Figures 5A, 5B](#pgen-1004815-g005){ref-type="fig"}, [S1](#pgen.1004815.s001){ref-type="supplementary-material"} and [S5](#pgen.1004815.s005){ref-type="supplementary-material"}). Moreover, loss of *NDUFA10* only very minimally reduced the degree of mitophagy ([Figures 5C, 5D](#pgen-1004815-g005){ref-type="fig"}, and [S6](#pgen.1004815.s006){ref-type="supplementary-material"}). We also found no effect of *NDUFA10* knockdown on PINK1 stabilization following mitochondrial depolarization ([Figure S7](#pgen.1004815.s007){ref-type="supplementary-material"}). These data indicate that *NDUFA10* does not play a significant role in PINK1/Parkin mediated mitophagy and suggests that the *in vivo* rescue was unlikely via the mitophagy pathway.

To further exclude a role for mitophagy in the rescue of *pink1* mutants, we assessed *in vitro* whether *NDUFA10* overexpression could promote CCCP-induced Parkin translocation in the absence of *PINK1*. Encouragingly, re-expression of either *NDUFA10* or *ND42* almost completely restored Parkin translocation reduced by *NDUFA10* knockdown ([Figures 6A and 6C](#pgen-1004815-g006){ref-type="fig"}). However, when Parkin translocation was completely blocked by loss of *PINK1*, this was not rescued by expression of either *NDUFA10* or *ND42* ([Figures 6A and 6D](#pgen-1004815-g006){ref-type="fig"}). These results support the idea that the rescue seen *in vivo* is unlikely due to activated mitophagy, raising the question of what mechanism is responsible.

![*NDUFA10/ND42* overexpression does not restore CCCP-induced Parkin translocation in the absence of *pink1*.\
(A) Quantification of the percentage of cells showing mitochondrially localized Parkin following 4 hours CCCP treatment of HeLa cells stably expressing YFP-Parkin transfected with (B) control siRNA, (C) *NDUFA10* siRNA, or (D) *PINK1* siRNA treatment and transfection with *NDUFA10* or fly *ND42* expression constructs. Scale bar  = 20 µm. \* *P*\<0.05, \*\*\* *P*\<0.001, One-way ANOVA with Bonferroni correction compared to respective control siRNA treatment.](pgen.1004815.g006){#pgen-1004815-g006}

*ND42* overexpression restores CI activity in *pink1* mutants {#s2e}
-------------------------------------------------------------

As loss of *PINK1* has been reported to cause decreased CI activity [@pgen.1004815-Morais1], we reasoned that suppression of *pink1* mutants by *ND42* overexpression may be due to restoration of CI activity. As previously reported, we observed a CI deficiency in *pink1* mutant flies, leading to decreased ATP production ([Figures, 7A and 7B](#pgen-1004815-g007){ref-type="fig"}). We found that *ND42* overexpression was indeed able to completely restore both CI activity and ATP levels *in vivo* ([Figure 7A and 7B](#pgen-1004815-g007){ref-type="fig"}). Extending these analyses to *parkin* mutants, we saw a non-significant decrease in CI activity in *parkin* mutants that remained unchanged by *ND42* overexpression ([Figure 7C](#pgen-1004815-g007){ref-type="fig"}). Similarly, the significant depletion of ATP evident in *parkin* mutants was not rescued by *ND42* overexpression ([Figure 7D](#pgen-1004815-g007){ref-type="fig"}), consistent with a lack of phenotypic rescue by *ND42* overexpression. Interestingly, we also found that *sicily* overexpression was able to completely restore CI activity in *pink1* mutants ([Figure 7A](#pgen-1004815-g007){ref-type="fig"}), while the increase in ATP levels was not significant ([Figure 7B](#pgen-1004815-g007){ref-type="fig"}). Similar to *ND42*, *sicily* overexpression had no effect in *parkin* mutants ([Figures 7C and 7D](#pgen-1004815-g007){ref-type="fig"}).

![*ND42* and *sicily* overexpression can rescue complex I and ATP deficiencies in *pink1* but not *parkin* mutant flies.\
*ND42* or *sicily* was overexpressed in (A, B) *pink1^B9^* mutants or (C, D) *park^25^* mutants. Charts show (A, C) the ratio of complex I to citrate synthase (CS) activity, and (B, D) relative ATP levels, normalized to control. Histograms indicate mean ± s.e.m. Overexpression was driven by the ubiquitous driver *da-GAL4*. Control genotype is *da-GAL4*/+. \*\* *P*\<0.01, \*\*\*\* *P*\<0.0001, One-way ANOVA with Bonferroni correction. Comparisons are with *pink1^B9^* or *park^25^* mutants, as appropriate.](pgen.1004815.g007){#pgen-1004815-g007}

Analysis of ND42 Ser-250 phospho-variants in the rescue of *pink1* mutant locomotion and CI activity {#s2f}
----------------------------------------------------------------------------------------------------

While this work was in preparation, Morais et al [@pgen.1004815-Morais2] reported that NDUFA10 lacked phosphorylation at serine-250 in the absence of PINK1, and that expression of phospho-mimetic NDUFA10/ND42 specifically reversed *PINK1* deficits in various model systems, including restoring CI activity in mammalian systems and synaptic phenotypes in *Drosophila pink1* mutants. Our preceding data concur that overexpression of *ND42* can rescue some *pink1* mutant phenotypes (and not others), but interestingly we found that this can be achieved with expression of the wild type version without a specific requirement for the phospho-mimetic.

To further explore the potential role of Ser-250 phosphorylation in these assays, we tested in parallel our existing lines (previously reported in [@pgen.1004815-Vilain1]) and those of Morais et al [@pgen.1004815-Morais2] and of the yeast equivalent of CI, *NDI1* [@pgen.1004815-Vilain1]. As before, we found that expression of the previous WT transgene (designated *ND42^HB^*) significantly rescued *pink1* climbing and flight defects ([Figures 8A and 8B](#pgen-1004815-g008){ref-type="fig"}). We also found that the Morais et al. transgenes (designated *ND42^BDS^*) expressing either WT or phospho-mimetic (SD) also partially rescued climbing, albeit to a lesser extent ([Figure 8A](#pgen-1004815-g008){ref-type="fig"}). The WT version of these lines did not statistically improve flight ability whereas the SD did provide a modest rescue ([Figure 8B](#pgen-1004815-g008){ref-type="fig"}). We also found that the non-phosphorylatable version (SA) provided significant rescue of climbing, equivalent to the phospho-mimetic, but again did not rescue flight ([Figure 8A and 8B](#pgen-1004815-g008){ref-type="fig"}). Notably, in these assays *NDI1* expression significantly rescued climbing but not flight ability ([Figure 8A and 8B](#pgen-1004815-g008){ref-type="fig"}), consistent with previous observations [@pgen.1004815-Vilain1].

![Analysis of ND42 Ser-250 phospho-variant rescue of *pink1* mutant climbing defect and complex I deficiency.\
Transgenes from different sources, labeled 'HB' [@pgen.1004815-Zhang1] and 'BDS' [@pgen.1004815-Morais2], expressing wild type *ND42* (WT), non-phosphorylatable (SA) or phospho-mimetic (SD) variants of Ser-250 were tested for rescue of climbing (A), flight (B) and complex I (C) deficiencies in *pink1^B9^* mutants. For comparison, transgenic expression of the yeast complex I equivalent, *NDI1*, was also tested. Overexpression was driven by the ubiquitous driver *da-GAL4*. Control genotype is *da-GAL4*/+. \* *P\<*0.05, \*\* *P\<*0.01, \*\*\*\* *P*\<0.0001, One-way ANOVA with Bonferroni correction. Comparisons are with *pink1^B9^* mutants unless otherwise shown.](pgen.1004815.g008){#pgen-1004815-g008}

To better understand the relationship between the behavioral rescue and CI activity, and to assess functional efficacies of the various transgenic lines, we tested the ability of the phospho-variants transgenes to rescue the CI deficiency in *pink1* mutants. We found that expression of all phospho-variants were able to fully restore CI activity in *pink1* mutants ([Fig. 8C](#pgen-1004815-g008){ref-type="fig"}). The degree of rescue was similar to that seen with the previous WT transgene ([Fig. 7A](#pgen-1004815-g007){ref-type="fig"}), consistent with an equivalent level of expression between these lines ([Fig. S1G](#pgen.1004815.s001){ref-type="supplementary-material"}). Interestingly, while we see the highest level of CI activity with the phospho-mimetic (SD), we also see a substantial rescue by the phopho-null (SA) in this *in vitro* assay.

Overexpression of *parkin* rescues *pink1* mutants but does not restore CI activity {#s2g}
-----------------------------------------------------------------------------------

The ability of multiple transgenes that restore CI activity to at least partially rescue climbing behavior supports the idea that promoting CI activity is differentially beneficial in *pink1* mutants but not *parkin* mutants and may hint at different underlying causes of pathogenicity. However, a puzzling aspect of this is the long-standing observations that *parkin* overexpression is sufficient to almost completely rescue many *pink1* mutant phenotypes ([Figures 9A and 9B](#pgen-1004815-g009){ref-type="fig"}, and [@pgen.1004815-Clark1], [@pgen.1004815-Park1], [@pgen.1004815-Exner1], [@pgen.1004815-Yang2]). Since, to our knowledge, it had never been reported, we tested whether the rescue may be due to restoration of CI activity in *pink1* mutants. Surprisingly, we found that *parkin* overexpression mildly improved ATP levels but did not restore CI function ([Figures 9C and 9D](#pgen-1004815-g009){ref-type="fig"}). Hence, these genetic interactions further support independent and separable functions of PINK1 and Parkin.

![Overexpression of *parkin* can rescue behavioral phenotypes in *pink1* mutants but not complex I deficiency.\
Analysis of (A) climbing and (B) flight ability in *pink1^B9^* mutants overexpressing *parkin*. Charts show (C) the ratio of complex I to citrate synthase (CS) activity, and (D) relative ATP levels, normalized to control. Histograms indicate mean ± s.e.m. Overexpression was driven by the ubiquitous driver *da-GAL4*. Control genotype is *da-GAL4*/+. \* *P\<*0.05, \*\* *P\<*0.01, \*\*\* *P\<*0.001, \*\*\*\* *P*\<0.0001, One-way ANOVA with Bonferroni correction. Comparisons are with *pink1^B9^* mutants.](pgen.1004815.g009){#pgen-1004815-g009}

Discussion {#s3}
==========

PINK1 and complex I function {#s3a}
----------------------------

PINK1 and Parkin have long been genetically linked in a common pathway that promotes mitochondrial homeostasis at least partly by directing the autophagic degradation of dysfunctional mitochondria as a mechanism of mitochondrial quality control. While this model potentially explains the occurrence of CI deficiency, oxidative stress, calcium dysregulation and elevated mtDNA mutations seen in patient tissues, and the age-related onset of PD [@pgen.1004815-Exner2], other models have been proposed to explain the pathological consequences of PINK1 and Parkin deficiency. Moreover, many mechanistic details by which the PINK1-Parkin pathway functions remain unexplained. To address these matters, we conducted an RNAi screen to identify genes whose loss-of-function either phenocopied or suppressed a *pink1* RNAi phenotype. We have identified a number of genes that fulfill these criteria (discussed below) but focused our current investigation on *ND42/NDUFA10* given the extensive literature implicating CI deficiency in PD pathogenesis and the fact that CI deficiency has previously been reported in *PINK1* mutant models and patient samples.

Loss of *ND42*/*NDUFA10* phenocopies the effect of *pink1* loss on mitochondrial morphology in *Drosophila* cells, and *ND42* overexpression rescues the *pink1* mutant phenotypes. However, *NDUFA10* knockdown has only modest effects on mitophagy, supporting a separate link between CI and PINK1 function. The simplest interpretation of these findings is that PINK1 normally regulates ND42/NDUFA10 abundance or activity through direct phosphorylation. Indeed, it was recently reported that NDUFA10 lacks phosphorylation at Ser-250 in *Pink1^-/-^* cells [@pgen.1004815-Morais2], although it remains to be determined whether PINK1 directly or indirectly regulates NDUFA10 phosphorylation. Moreover, it was reported that expression of a phospho-mimetic version of ND42/NDUFA10 specifically rescued phenotypes in multiple *PINK1* deficient systems, while an S250A mutant version of ND42/NDUFA10 that is incapable of being phosphorylated was unable to confer rescue. Consistent with this we find that, from equivalent expression levels, the phospho-mimetic (SD) provides a slightly better phenotypic rescue than the other variants, and likewise promotes a higher CI activity. Nevertheless, our results also show that the non-phosphorylatable S250A version is still able to restore CI activity and significantly rescue the climbing deficit in *pink1* mutant flies.

While further studies are needed to clarify the functional relationship between PINK1 and NDUFA10 in the regulation of CI, our findings provide further support mounting evidence that many manipulations that promote CI activity -- overexpression of *NDUFA10*, *sicily*, *heix*, *Ret*, *dNK*, *TRAP1* and *NDI1*, or treatment with vitamin K, deoxynucleosides or folic acid [@pgen.1004815-Morais2], [@pgen.1004815-Vilain1], [@pgen.1004815-Klein1]--[@pgen.1004815-Zhang2] -- can rescue *pink1* mutants, suggesting a more general defect underlies CI deficiency in loss of *pink1*. We hypothesize that the loss of CI activity in *pink1* mutants may be due to a general de-stabilization of CI. Assembly is a particular challenge for such a large, multi-subunit complex and occurs in a stepwise process that is highly regulated by many factors [@pgen.1004815-Lazarou1]. Even its association with other ETC complexes in supercomplexes affects CI\'s stability [@pgen.1004815-AcinPerez1]. There is evidence for reduced complex stability in *pink1* mutants, though this may not be specific to CI [@pgen.1004815-Tufi1], [@pgen.1004815-Liu1], [@pgen.1004815-Amo1]. One possibility is that PINK1 influences CI stability by directly promoting the assembly of CI, which may be regulated by NDUFA10.

The current findings also further support that the mechanism by which PINK1 influences CI activity appears to be separable from its well-characterized role in mitophagy, since, in agreement with some studies [@pgen.1004815-Morais1], [@pgen.1004815-Vilain1] but in contrast to others [@pgen.1004815-Flinn1], [@pgen.1004815-Mortiboys1], [@pgen.1004815-Muftuoglu1], we do not find clear evidence of CI deficiency in *parkin* mutants flies. Moreover, it was unexpected to find that overexpression of *parkin* does not rescue the CI deficiency in *pink1* mutants, because substantial previous work has shown that parkin overexpression rescues all of the other *pink1* phenotypes, and because a prediction of the PINK1-parkin mitophagy pathway is that activation would trigger the selective removal of mitochondria deficient in CI activity. This finding suggests that CI deficiency alone cannot fully account for adult locomotor phenotypes seen in *pink1* mutants. Further studies are needed to clarify full spectrum of cellular defects in *pink1* and *parkin* mutants and their relative importance to the pathologic mechanism.

Consideration of other screen hits {#s3b}
----------------------------------

The present screen analyzed the effect of ∼600 genes comprising mostly genes with homology to kinase or phosphatase domains. Other hits from this screen, identifying both phenocopiers and suppressors, could also be attractive candidates as potential new factors of pink1/Parkin function. Notably several hits play a role in lipid biology. This is particularly noteworthy in light of our recent report that another RNAi screen identified the master regulator of lipogenesis, *SREBF1*, to affect pink1/Parkin-mediated mitophagy [@pgen.1004815-Ivatt1].

The phenocopier *Sphingosine kinase 1* and the suppressor *easily shocked* (encoding *Drosophila* Ethanolamine Kinase) are involved in phospholipid metabolic pathways. Sphingosine kinase catalyzes the production of sphingosine-1-phosphate (S1P), a key signaling molecule affecting cell growth and survival [@pgen.1004815-Olivera1]. While S1P affects many cellular processes perhaps the most intriguing is its role in calcium mobilization from the endoplasmic reticulum (ER) [@pgen.1004815-Choi1] since Parkin was recently shown to promote ER-mitochondrial calcium transfer [@pgen.1004815-Cali1]. Interestingly, the breakdown of S1P generates phosphoethanolamine, the enzymatic product of ethanolamine kinase and a precursor metabolite of the key phospholipid phosphatidylethanolamine (PE). Loss of mitochondrial PE has been shown to affect mitochondrial morphology, oxidative phosphorylation and even the formation of complex I-containing supercomplexes [@pgen.1004815-Tasseva1]. The identification of *four wheel drive* (encoding *Drosophila* phosphatidylinositol 4-kinase beta), which catalyzes the formation of PI(4)P, is also intriguing since mutations in *SYNJ1*, which encodes PI(4,5)P~2~ phosphatase, were identified in families with early onset parkinsonism [@pgen.1004815-Krebs1], [@pgen.1004815-Quadri1].

Also related to lipid biology is Nocturnin although a direct link to mitochondria biology is less obvious. Nocturnin encodes a circadian deadenylase thought to be involved in the rhythmic regulation of gene expression by removal of polyA tails from mRNAs. Mice lacking Nocturnin are resistant to diet-induced obesity and hepatic steatosis [@pgen.1004815-Stubblefield1], linking its function to lipid metabolism. Further studies will be needed to determine the extent to which lipids in general or specific lipids, and their regulated synthesis, impact on pink1/Parkin biology and regulation of mitochondrial dynamics and quality control. Nevertheless, this screen provides a resource for characterizing novel factors that regulate mitochondrial morphology.

Materials and Methods {#s4}
=====================

Cell culture {#s4a}
------------

*Drosophila* S2R+ cells were cultured in Schneider\'s medium (Gibco) containing 10% (vol/vol) heat-inactivated fetal bovine serum (Sigma), Penicillin 10 units/ml (Sigma) and Streptomycin 10 µg/ml (Sigma). Cells were maintained in a 25°C incubator. HeLa cells were cultured in DMEM GLUTAMAX media (Gibco) containing 10% (vol/vol) heat-inactivated fetal bovine serum (Sigma), Penicillin 10 units/ml (Sigma) and Streptomycin 10 µg/ml (Sigma). Cells were maintained in a 37°C incubator with 5% CO~2~. A stable transfected HeLa cell line expressing YFP-Parkin in pLVX-puro was cultured in DMEM GLUTAMAX media (Gibco) containing 10% (vol/vol) heat-inactivated fetal bovine serum (Sigma), Penicillin 10 units/ml (Sigma) and Streptomycin 10 µg/ml (Sigma). Cells were maintained in a 37°C incubator with 5% CO~2~.

RNAi screening and high-content microscopy {#s4b}
------------------------------------------

The kinome/phosphatome sub-library was generated based upon the second generation *Drosophila* dsRNA library (Heidelberg 2). Detailed information on amplicon targets is available online (<http://rnai-screening-wiki.dkfz.de/signaling/wiki/display/rnaiwiki/Drosophila+RNAi+libraries>). This sub-library was designed to contain all known and computed kinases and phosphatases, genes with some homology to these enzyme classes, but also some other genes of general interest. Library dsRNAs were plated at 250 ng in 5 µl of H~2~O into Perkin Elmer 384 well view plate (Product number: 6007470). Screen plates were arrayed with the inclusion of gaps to allow for the addition of user-specific controls. Here we added dsRNAs targeting *Marf*, *Drp1*, *OPA1*, *Fis1*, *pink1* and *parkin*. These controls consistently all showed the expected results. For the *pink1* RNAi background, 250 ng dsRNA against *pink1* was added to each well prior to screening. A 'double dose' of dsRNA did not appear to affect mitochondrial morphology (see below). 15,000 *Drosophila* S2R+ cells were added to each well in 30 µl of Schneider\'s medium (Gibco) without FBS (Sigma). Plates were incubated at 25°C for 1 hour in which time dsRNAs are taken up by the cells. Following this incubation 30 µl of Schneider\'s medium (Gibco) containing 20% FBS (v/v) was added. The plates were then sealed and incubated at 25°C incubator for 4 days. Cells were stained with 100 nM Mitotracker Red (Invitrogen, M7512) and 20 µg/ml Hoechst 33342 (Invitrogen, H3570) for 15 minutes. Media was replaced and imaging was performed on live cells. Imaging was performed on an IN Cell Analyzer 1000 (GE Healthcare) automated microscope using a 40× air objective (Nikon, 0.60 NA).

Mitochondrial morphology analysis {#s4c}
---------------------------------

Cells were prepared identically as for the high-throughput screening conditions, except for wild type where background 250 ng dsRNA targeting *DsRed* was added to each condition to mirror the 'double dose' of dsRNA in the *pink1* background. Cells were imaged live under ambient conditions on a Deltavision RT deconvolution wide field microscope (Olympus, 100× objective, 1.4 NA) using 8 well µ-Slides (Ibidi), with 10 images taken per condition. Cells were scored for their gross mitochondrial morphology by eye with the scorer blinded to the experimental conditions. Where rotenone (20 µM) was used, cells were treated for 2 hours before mitochondrial morphology was analysed. A score would be assigned for a whole field of view and an average score would be calculated for the 10 images per condition. A score of 1 would be given to a field of view that had mainly fragmented mitochondria. A score of 2 would be given to a field of view that had a mainly wild type mitochondrial network with a mix of short-round and long-tubular mitochondria. A score of 3 would be given to a field of view that had mainly tubular mitochondria. A score of 4 would be given to a field of view that had mainly clumped mitochondria where the mitochondria had formed a single or few large peri-nuclear clusters.

RNAi reagents {#s4d}
-------------

*Drosophila* gene dsRNAs were generated using the MEGAscript T7 Kit (Ambion), using T7-flanked DNA amplicons from the library as template. Control dsRNA for *Drosophila* cell qRT-PCR analysis was a 782 bp sequence targeted against *C. elegans* gene *R06F6.2* which has no ∼21mer homology within the *Drosophila* genome. siRNAs targeting human genes were obtained from the siGENOME SMARTpool collection (Dharmacon) as follows: control siRNA is Non-Targeting siRNA Pool \#1 (product code; D-001206-13-20); *PINK1* (product code; M-004030-02); *NDUFA10* (product code; M-006752-00).

Quantitative real-time PCR {#s4e}
--------------------------

Total RNA from live cells was prepared from three replicates of each dsRNA treatment using RNeasy (Qiagen). RNA concentration was then determined spectrophotometrically. Once treated with DNase, total RNA was reverse-transcribed using RETROscript (Ambion) or Protoscript (NEB) according to the manufacturer\'s protocol. Quantitative PCR was performed using SYBR Green (Sigma) on a MyIQ real time PCR detection system (Bio-Rad). Each PCR included three technical replicates, which were repeated as three biological replicates. Levels for each transcript were normalized to a 18S rRNA (*Drosophila*: *18SrRNA*; Human: *RNA18S5*) control by the 2^-ΔΔ*CT*^ method.

For *Drosophila* genes, primers used were:

18S - Forward: TCTAGCAATATGAGATTGAGCAATAAG

18S - Reverse: AATACACGTTGATACTTTCATTGTAGC

pink1 - Forward: GACGACCCTCGCACATAA

pink1 - Reverse: AACAGTCCGGAGATCCTACAG

ND42 - Forward: CGTTTCGATGTCCCGGAGCT

ND42 - Reverse: GTCTGCATTGTAGCCAGGAC

CG7712 - Forward: CGCAATGTGACCGACATCCG

CG7712 - Reverse: CGCATGATATGGCCTTCTG

For human genes, primers used were:

18S - Forward: CAGCCACCCGAGATTGAGCA

18S - Reverse: TAGTAGCGACGGGCGGTGTG

PINK1 - Forward: GCCGGACGCTGTTCCTCGTT

PINK1 - Reverse: TGGACACCTCTGGGGCCATC

NDUFA10 - Forward: GATCCGAGAAGCAATGATG

NDUFA10 - Reverse: TGGAGCGCTCCAACACAACA

Antibodies {#s4f}
----------

The following primary antibodies were used, mouse anti-ATP5A (MS507, MitoSciences; 1∶2000), rabbit anti-GFP (ab6556, Abcam; 1∶5000). Secondary antibodies used were rabbit polyclonal anti-mouse IgG-H&L (DyLight 594, Invitrogen; 1∶5000) and goat anti-rabbit IgG (Alexa Fluor 488, Invitrogen; 1∶5000).

Parkin translocation and mitophagy assays {#s4g}
-----------------------------------------

YFP-Parkin HeLa cells were reverse-transfected with siRNAs using DharmaFECT 1 (Dharmacon). For Parkin translocation, cells were incubated for 4 days then treated with 10 µM CCCP or equivalent volume of the solvent (EtOH) for 4 hours. For mitophagy, cells were incubated for 3 days then treated with 10 µM CCCP or equivalent volume of the solvent (EtOH) for 24 hours. Cells were fixed in ice-cold methanol for 10 minutes and washed in PBS. Mitochondrial staining was achieved by using anti-ATP5A antibody. Imaging was performed on an Olympus FV1000 confocal microscope (Olympus, 60× oil objective, 1.25 NA). For Parkin translocation, cells were scored for the accumulation of YFP-Parkin on mitochondria. For mitophagy, cells were scored for mitochondrial load based on having a normal load of mitochondria, few mitochondria or no mitochondria. At least 20 cells were scored per treatment and 3 biological replicates were performed.

PINK1 accumulation assay {#s4h}
------------------------

HeLa cells were reverse-transfected with siRNAs using DharmaFECT 1. After 3 days cells were transfected with PINK1-EGFP using Effectene (Qiagen). After a further 1 day cells were treated with 10 µM CCCP or equivalent volume of the solvent (EtOH) for 1 hour before fixation with ice-cold methanol for 10 minutes and washed in PBS. Immunofluorescence was performed using anti-ATP5A and anti-GFP antibodies, and appropriate fluorescent secondary antibodies. Imaging was performed on an Olympus FV1000 confocal microscope. Cells were scored for the accumulation of PINK1-EGFP on mitochondria. At least 20 cells were scored per treatment and 3 biological replicates were performed.

TMRM assay {#s4i}
----------

TMRM assay to measure mitochondrial membrane polarity was done as previously described [@pgen.1004815-Mortiboys1]. Briefly, HeLa cells were reverse-transfected with siRNAs using DharmaFECT for 4 days. Cells were then treated with 10 µM CCCP or equivalent volume of the solvent (EtOH) for 1 hour. Cells were incubated with 50 nM TMRM (VTX668, Fisher) in PBS with 10 µM CCCP or equivalent volume of solvent for 30 minutes, then washed in PBS with 10 µM CCCP or equivalent volume of solvent 5 times. TMRM fluorescence was read on a spectrophotometer at 550 nm (Berthold technologies Mithras LB940). Triplicate readings were taken from 3 biological replicates.

*Drosophila* genetics {#s4j}
---------------------

*Drosophila* were raised under standard conditions at 25°C on food consisting of agar, cornmeal and yeast. *pink1^B9^* mutants [@pgen.1004815-Park1] were provided by J. Chung (KAIST). *park^25^* mutants, fertility tests, flight and climbing assays were performed as previously described [@pgen.1004815-Greene1], [@pgen.1004815-Tain1]. *w^1118^* and *da-GAL4* strains were obtained from the Bloomington *Drosophila* Stock Center (Bloomington, IN). UAS-*ND42*-RNAi lines (GD: 14444; KK: 101787) were obtained form the Vienna *Drosophila* Resource Centre [@pgen.1004815-Dietzl1]. UAS-*ND42*, UAS-*ND42*-HA and UAS-*sicily* have been described previously [@pgen.1004815-Zhang1] and were a gift from H. Bellen (Baylor College of Medicine). The additional UAS-*ND42* lines (WT, SA and SD) from Morais et al. [@pgen.1004815-Morais2] were provided by Patrik Verstreken.

Measurement of complex I activity {#s4k}
---------------------------------

Mitochondria-enriched fractions were prepared from whole adult male flies (∼3 days old) with the indicated genotype (10 flies were used for each sample). Flies were gently crushed in chilled isolation buffer (250 mM sucrose, 10 mM Tris-HCl, pH 7.4, 0.15 mM MgCl~2~) using a plastic pestle homogenizer, then centrifuged twice at 500×g for 5 minutes at 4°C to remove debris. The supernatant was centrifuged 5000×g for 5 minutes at 4°C. The resulting pellet containing mitochondria was re-suspended in the isolation buffer or assay buffers. Complex I activity was measured using a modified method from Birch-Machin et al [@pgen.1004815-BirchMachin1]. Briefly, samples were subjected to 3 cycles of freeze-thaw in liquid nitrogen. Complex I activity was determined by following the oxidation of NADH at 340 nm with a reference wavelength of 425 nm (ε = 6.22 mM^−1^ cm^−1^) at 30°C using a BMG Labtech FLUOStar plate reader. The assay buffer contained 25 mM KH~2~PO~4~, 5 mM MgCl~2~, (pH 7.2), 3 mM KCN, 2.5 mg per ml BSA, 50 µM ubiquinone, 2 µg/ml antimycin A and mitochondrial extract. The baseline was recorded for 5 minutes and the reaction was started with 125 µM NADH measured for 30 minutes, 15 µg/ml rotenone was added to inhibit the reaction and measured for 15 minutes. The results are expressed as µmol NADH oxidised/min/citrate synthase activity. Citrate synthase was measured by following the production of 5-thio-2-nitrobenzoate at 30°C using a BMG Labtech FLUOStar plate reader after samples had undergone 3 cycles of freeze-thaw in liquid nitrogen. The assay buffer was 100 mM Tris HCl (pH 8.0), 0.1 mM DTNB, 50 µM acetyl Coenzyme A, 0.1% Triton X-100 and mitochondrial extract per well. The baseline was recorded for 5 minutes at 412 nm, then the reaction was started by the addition of 0.5 mM oxaloacetate acid and the rate was recorded for 15 minutes.

ATP assays {#s4l}
----------

Five male flies (3 days old) were homogenized in 100 µl of 6 M guanidine-HCl in extraction buffer (100 mM Tris, 4 mM EDTA, pH 7.8) to inhibit ATPases. Homogenized samples were subjected to rapid freezing in liquid nitrogen, followed by boiling for 3 min. Samples were cleared by centrifugation, and supernatant was diluted (1/100) with extraction buffer and mixed with a luminescent solution (CellTiter-Glo Luminescent Cell Viability Assay, Promega, Fitchburg, WI, USA). Luminescence was measured on a Varioskan™ Flash Multimode Reader (Thermo Scientific, Waltham, MA, USA). The relative ATP levels were calculated by dividing the luminescence by the total protein concentration, which was determined by the Bradford method.

Statistical analyses {#s4m}
--------------------

For Parkin translocation, mitophagy and PINK1 stabilization, statistical significance was calculated by using Student\'s *t*-test on triplicate experiments comparing against control siRNA/dsRNAs of the equivalent experimental condition. Biochemical and behavioral assays in *Drosophila* were analyzed by one-way ANOVA with Bonferroni correction. Male fertility was analyzed by Chi-square test.

Supporting Information {#s5}
======================

###### 

Quantitative real-time PCR measurement for relative gene expression in RNAi knockdown and transgenic overexpression conditions. (A--C) *Drosophila* S2R+ cells treated with dsRNAs for the indicated genes. Message abundance of the respective gene is shown relative to control dsRNA treatment. (D--E) HeLa cells transfected with the indicated siRNAs. Message abundance of the respective gene is shown relative to control (ctrl) siRNA treatment. (F) The four *NDUFA10* SMARTpool siRNAs were tested individually and compared to combined SMARTpool and shown relative to ctrl. Transcript levels are normalized against a housekeeping gene, *18S rRNA*. All differences are highly significant (*P*\<0.001) compared to the relevant control. (G, H) Relative expression levels in flies overexpressing *ND42* or *sicily*, as indicated, driven by *da-GAL4*. \*\* *P\<*0.01, \*\*\* *P\<*0.001, one-way ANOVA with Bonferroni correction (G) or Student\'s *t*-test (H) compared with control genotype (*da-GAL4*/+).

(TIFF)

###### 

Click here for additional data file.

###### 

*ND42* or *sicily* overexpression does not rescue *pink1* or *parkin* mutant male sterility. *ND42* or *sicily* was overexpressed by *da-GAL4* in either *pink1* (A) or *parkin* (B) mutant males and fertility was assessed (n\>45 males of each genotype). Fertility was almost completely restored by *da-GAL4* induced re-expression of *pink1* or *parkin*. Control genotype is *da-GAL4*/+. \*\*\*\* *P*\<0.0001, Chi-square test. Comparisons are with control genotype unless otherwise indicated.

(TIFF)

###### 

Click here for additional data file.

###### 

RNAi knockdown of *sicily* causes mitochondrial hyperfusion. (A) *Drosophila* S2R+ cells treated with indicated dsRNAs and stained with MitoTracker Red to visualize mitochondria. (B) Cells were scored as in [Fig. 2](#pgen-1004815-g002){ref-type="fig"} for relative mitochondrial morphology. Scale bar  = 5 µm. \*\* *P\<*0.01, \*\*\* *P\<*0.001, Student\'s *t*-test compared with control dsRNA.

(TIFF)

###### 

Click here for additional data file.

###### 

Categorization of mitochondrial content during mitophagy. HeLa cells transiently transfected to express YFP-Parkin (green) induce mitophagy following prolonged exposure to CCCP. Mitochondrial content can be monitored by ATP5A immunostaining (red). Cells with normal mitochondrial content, as seen before toxification, are categorized as "High". Depolarized mitochondria become aggregated and in a perinuclear region, and termed "Low". Cells which have undergone complete mitophagy have a mitochondrial content scored as "None".

(TIFF)

###### 

Click here for additional data file.

###### 

Individual *NDUFA10* siRNAs attenuate CCCP-induced Parkin translocation. (A) In HeLa cells stably transfected to express YFP-Parkin, before CCCP toxification (0 h) YFP-Parkin (green) has a diffuse cytoplasmic distribution in control (ctrl) siRNA treated cells. Following 4 h CCCP, YFP-Parkin co-localizes with mitochondria labeled with ATP5A immunostaining (red). *PINK1* siRNA treatment almost completely abolishes YFP-Parkin translocation. Individual *NDUFA10* siRNAs, \#1 and \#3, significantly reduce YFP-Parkin translocation. (B) Quantification of YFP-Parkin translocation as in A, scored in triplicate experiments. n\>30 cells per experiment. Scale bar  = 20 µm. \*\*\* *P\<*0.001, Student\'s *t*-test compared with control siRNA.

(TIFF)

###### 

Click here for additional data file.

###### 

Individual *NDUFA10* siRNAs reduce CCCP-induced mitophagy. (A) Stably transfected HeLa cells expressing YFP-Parkin, before CCCP treatment (0 h, ctrl) have a normal ("High") mitochondrial content. Following 24 h treatment with CCCP, a high proportion of control cells (ctrl) show complete degradation ("none") or perinuclear aggregated ("low") mitochondria, visualized by ATP5A immunostaining (red). *PINK1* siRNA treatment almost completely abolishes mitophagy. Individual *NDUFA10* siRNAs, \#1 and \#3, significantly reduce mitophagy. (B) Quantification of mitochondrial content as in A, scored in triplicate experiments. n\>30 cells per experiment. Scale bar  = 20 µm. \* *P\<*0.05, \*\* *P\<*0.01, \*\*\* *P\<*0.001, Student\'s *t*-test compared with control siRNA.

(TIFF)

###### 

Click here for additional data file.

###### 

*NDUFA10* knockdown does not affect CCCP-induced pink1 stabilization. (A) HeLa cells transiently expressing PINK1-GFP and treated with control (ctrl) siRNA. Before CCCP toxification (0 h) PINK1-GFP (green) has a diffuse distribution. Following 1 h CCCP PINK1-GFP becomes stabilized and accumulates on mitochondria, labeled with ATP5A immunostaining (red). Boxed areas are shown magnified in images below. (B) Quantification of PINK1-GFP stabilization as in A. Charts indicate mean ± s.d. of triplicate experiments. n\>15 cells per experiment. Scale bars; low mag.  = 20 µm, zoom  = 4 µm.

(TIFF)

###### 

Click here for additional data file.
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